Exagen Launches New Diagnostic Assays for Bowel Disease at Digestive Disease Week Conference
Company signs partnership agreement with Clinical Reference Laboratory
The eXaIBStest identifies patients with IBS, while the eXaIBD test identifies patients with IBD. Compared with other available laboratory tests, Exagen’s assays produce significantly more accurate test results, providing physicians with more reliable data to aid in diagnosing their patients. The tests were invented using Coperna(TM), Exagen’s proprietary genomic data mining software.
“Until now, physicians have relied on a wide range of tests and procedures to aid in the diagnosis of IBS and IBD, including blood tests with limited diagnostic performance,” said Exagen President and CEO
Exagen’s tests are RNA-based, and require a single tube of peripheral blood. To support the front-end specimen handling and logistics, Exagen has signed a partnership agreement with
“Exagen Diagnostics has developed an extremely promising series of diagnostic assays for gastrointestinal diseases,” said
About Exagen Diagnostics, Inc.
Exagen Diagnostics is a CLIA-registered molecular diagnostics laboratory with a growing menu of proprietary, internally developed genomic tests. For more information, visit www.exagen.com.
About Clinical Reference Laboratory, Inc (CRL Global Services)
Established in 1979, CRL Global Services is a privately held reference laboratory in
SOURCE Exagen Diagnostics, Inc.